• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Topics » General Psychiatry » Files

General Psychiatry

TADALAFIL (Cialis) Fact Sheet [G]

November 29, 2023

We have fewer data for tadalafil in the psychiatric setting; however, compared to other agents in the class, its long duration of action may improve spontaneity, and the lack of interaction with meals may offer advantages. Tadalafil is an especially good choice for men who have both prostatic hypertrophy and erectile dysfunction (ED). From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

PERPHENAZINE (Trilafon) Fact Sheet [G]

November 29, 2023

Perphenazine, first introduced in 1957, is an older first-generation agent that enjoyed a big boost in popularity after the 2005 CATIE trial found it to be as effective as most second-generation agents with minimal weight gain or metabolic problems. It has become a favorite go-to antipsychotic for many clinicians—an effective, well-tolerated, and inexpensive alternative to second-generation antipsychotics. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

BREMELANOTIDE (Vyleesi) Fact Sheet

November 29, 2023

Bremelanotide (marketed as the “female Viagra”) is a melanocortin receptor agonist that is modestly effective in increasing sexual desire in women, though it doesn’t affect sexual functioning. Disadvantages include the fact that it requires self-injection and carries a 40% rate of nausea as a side effect. It’s worth trying in some patients, but don’t expect miracles. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

BENZTROPINE (Cogentin) Fact Sheet [G]

November 29, 2023

Benztropine is an anticholinergic medication that is the go-to agent for treating and preventing antipsychoticinduced extrapyramidal symptoms (EPS). From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

AVANAFIL (Stendra) Fact Sheet

November 29, 2023

Avanafil is the newest PDE-5 inhibitor to come to market. Its potential advantage is a somewhat faster onset than any of the other ED drugs. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

CARIPRAZINE (Vraylar) Fact Sheet

November 29, 2023

Cariprazine, like aripiprazole and brexpiprazole, is a partial dopamine agonist. Some preliminary data imply that it might be effective for negative symptoms, but it’s too soon to tell. Beyond that, it appears similar to the other two partial dopamine agonists with regard to akathisia and minimal weight gain. It is available as a brand name only and is therefore very expensive (as opposed to aripiprazole, which has gone generic). From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

HYDROXYZINE (Atarax, Vistaril) Fact Sheet [G]

November 29, 2023

Hydroxyzine is an antihistamine that is a good non-addictive option when your patient needs a rapid-acting anxiolytic. But beware of its anticholinergic effects, especially in patients who take many doses throughout the day From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

BREXPIPRAZOLE (Rexulti) Fact Sheet

November 29, 2023

Brexpiprazole is a cousin of aripiprazole and is also a partial dopamine agonist. While it has a very similar efficacy profile to aripiprazole, it was recently awarded approval for treatment of agitation in Alzheimer’s dementia—the first drug to gain this indication. However, effect sizes were small, and safety in the elderly remains a concern. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

QUETIAPINE (Seroquel, Seroquel XR) Fact Sheet [G]

November 29, 2023

Quetiapine’s low risk for EPS and broad spectrum of efficacy make it an appealing first-choice agent. However, sedation, weight gain, and orthostasis may limit use. Dosing at bedtime, or switching to XR, may help reduce daytime sedation. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

Sialorrhea (Hypersalivation)

November 29, 2023

Excessive drooling, usually more severe at night. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

Previous 1 2 … 19 20 21 22 23 24 25 26 27 28 29 30 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2603816031.jpg
    General Psychiatry

    A Scam for Every Woman, Child, and Man: Part 2

    1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.